What is the average price target for LIFEMD INC (LFMD) stock?
14 analysts have analysed LFMD and the average price target is 9.44 USD. This implies a price increase of 129.57% is expected in the next year compared to the current price of 4.1099.
NASDAQ:LFMD • US53216B1044
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LIFEMD INC (LFMD).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-16 | Mizuho | Upgrade | Neutral -> Outperform |
| 2026-03-12 | Freedom Capital Markets | Maintains | Buy -> Buy |
| 2026-03-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-10 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-19 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-11-19 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-11-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-18 | Lake Street | Maintains | Buy -> Buy |
| 2025-11-18 | BTIG | Maintains | Buy -> Buy |
| 2025-11-18 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-08-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-08-06 | Lake Street | Maintains | Buy -> Buy |
| 2025-08-06 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-07-14 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-07-10 | Lake Street | Maintains | Buy -> Buy |
| 2025-04-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-11 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-01-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-12-10 | Lake Street | Initiate | Buy |
| 2024-12-04 | Mizuho | Initiate | Neutral |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 152.547M 28.19% | 154.824M 1.49% | 194.055M 25.34% | 228.51M 17.76% | 268.87M 17.66% | 237.56M -11.65% | |
| EBITDA YoY % growth | -7.889M 74.41% | -10.911M -38.30% | -361.2K 96.69% | 15.225M 4,315.12% | 32.64M 114.38% | 40.8M 25.00% | |
| EBIT YoY % growth | -14.489M 58.12% | -20.402M -40.81% | -7.67M 62.41% | -6.282M 18.09% | 4.177M 166.49% | 4.08M -2.32% | |
| Operating Margin | -9.50% | -13.18% | -3.95% | -2.75% | 1.55% | 1.72% | |
| EPS YoY % growth | -0.70 55.41% | -0.54 22.86% | -0.16 70.37% | -0.06 60.16% | 0.23 462.67% | -0.02 -108.82% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.15 -1,604.50% | -0.04 25.20% | -0.02 67.94% | 0.00 108.49% | 0.18 222.03% | 0.18 509.09% | 0.18 918.18% | 0.20 5,906.01% |
| Revenue Q2Q % growth | 49.385M -24.83% | 54.803M -11.92% | 58.368M -3.00% | 64.55M 37.73% | 70.976M 43.72% | 73.444M 34.01% | 73.674M 26.22% | 81.876M 26.84% |
| EBITDA Q2Q % growth | -1.943M -137.37% | 4.898M 7.10% | 5.989M -7.90% | 8.698M 701.51% | 8.082M 515.90% | 9.104M 85.87% | 10.275M 71.56% | 13.727M 57.82% |
| EBIT Q2Q % growth | -9.2M -461.78% | -2.261M -149.36% | -1.401M 28.84% | 1.059M 117.02% | 4.098M 144.54% | 3.918M 273.27% | 4.204M 400.01% | 4.741M 347.69% |
All data in USD
14 analysts have analysed LFMD and the average price target is 9.44 USD. This implies a price increase of 129.57% is expected in the next year compared to the current price of 4.1099.
LIFEMD INC (LFMD) will report earnings on 2026-05-04.
The consensus EPS estimate for the next earnings of LIFEMD INC (LFMD) is -0.15 USD and the consensus revenue estimate is 49.38M USD.
The number of analysts covering LIFEMD INC (LFMD) is 14.